Eye Therapies v. Slayback Pharma: Federal Circuit Reverses in Part and Remands
Eye Therapies LLC and Slayback Pharma LLC clashed at the Federal Circuit over US8293742B2, a patent covering preferential vasoconstriction compositions and methods of use. After 707 days, the court issued a split ruling — reversing in part, vacating the lower decision, and remanding — a complex outcome that leaves key patentability questions unresolved at the appellate level.
A split Federal Circuit ruling resets the vasoconstriction patent fight
Eye Therapies LLC brought this appeal to the United States Court of Appeals for the Federal Circuit (Case No. 23-2173) against Slayback Pharma LLC, challenging a prior ruling on the validity of US8293742B2. The patent, filed under application number US12/460941, covers preferential vasoconstriction compositions and methods of use — a technically specific pharmaceutical mechanism with direct relevance to ophthalmic and nasal decongestant product development. The case was filed on 24 July 2023 and closed 30 June 2025.
The Federal Circuit issued a divided outcome: the lower decision was reversed in part, vacated, and the matter remanded for further proceedings. The court also partially dismissed the appeal, suggesting that certain issues were not properly before it on procedural grounds. This combination of reversal, vacatur, and remand means the patentability determinations that stood below no longer carry binding force in their prior form, and the tribunal below must re-examine the contested issues consistent with the Federal Circuit’s guidance.
A 707-day resolution at the appellate level is consistent with complex patentability disputes involving ANDA or pharmaceutical invalidity proceedings at the Federal Circuit. The partial dismissal of the appeal suggests some claims or parties may have lacked standing or that certain issues were unripe, though the public record does not specify further. The remand leaves Eye Therapies with a meaningful opportunity to preserve patent rights, while Slayback faces continued uncertainty regarding freedom to operate around US8293742B2.
Filing to Appeal Dismissed in Part in 707 days
707 days from filing to close — above average for a Federal Circuit patent appeal
Federal Circuit reverses in part and vacates: what the ruling means for both parties
Reversed in part, vacated, and remanded — what this means
A Federal Circuit ruling of ‘reversed in part, vacated, and remanded’ is a compound disposition. ‘Reversed in part’ means the court found specific legal error in a portion of the lower tribunal’s ruling and overturned it. ‘Vacated’ nullifies the operative decision below, stripping it of legal effect. ‘Remanded’ sends the matter back for proceedings consistent with the appellate court’s direction. No final merits resolution emerges from this ruling alone.
Merits partially resolved — remand requiredEye Therapies gains appellate footing — but the fight continues
The reversal in part suggests Eye Therapies successfully challenged at least one aspect of the adverse patentability ruling below. Vacatur of the lower decision removes the prior finding as a controlling authority, which may restore negotiating leverage and licensing position. However, because the case is remanded, enforceability of US8293742B2 remains subject to further adjudication — the patent is neither finally upheld nor invalidated at this stage.
Patent validity unresolved — remand pendingSlayback loses the prior ruling — uncertainty extends
The vacatur of the decision below removes any prior patentability determination that may have favoured Slayback’s invalidity position. The reversal in part indicates the Federal Circuit found error in at least one element of the analysis on which Slayback may have relied. Slayback now faces renewed proceedings at the remand stage, and its freedom-to-operate position around US8293742B2 remains commercially uncertain until a final determination issues.
FTO position reset — remand exposureVasoconstriction IP landscape faces continued ambiguity
For competitors and generic entrants in the preferential vasoconstriction space, this outcome provides no safe harbour. The vacatur of the lower decision means any invalidity argument that depended on the prior ruling cannot be relied upon. Companies developing or marketing vasoconstriction compositions should treat US8293742B2 as a live enforcement risk and conduct updated FTO analysis pending the outcome of the remand proceedings.
Monitor remand — FTO review advisedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Eye Therapies, LLC | Company | Pharmaceutical IP licensor — holder of US8293742B2 covering preferential vasoconstriction compositionsSearch in Eureka ↗ |
| Defendant | Slayback Pharma, LLC | Company | Slayback Pharma LLC — specialty generic pharmaceutical manufacturerSearch in Eureka ↗ |
| Plaintiff counsel | Bryan Diner | Attorney | Counsel for Eye Therapies, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Charles E. Lipsey | Attorney | Counsel for Eye Therapies, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Christina JiHye Yang | Attorney | Counsel for Eye Therapies, LLCSearch in Eureka ↗ |
| Plaintiff counsel | James R. Barney | Attorney | Counsel for Eye Therapies, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Justin James Hasford | Attorney | Counsel for Eye Therapies, LLCSearch in Eureka ↗ |
| Plaintiff law firm | Finnegan, Henderson, Farabow, Garrett & Dunner, LLP | Law Firm | Representing Eye Therapies, LLCSearch in Eureka ↗ |
| Defendant counsel | Elaine Blais | Attorney | Counsel for Slayback Pharma, LLCSearch in Eureka ↗ |
| Defendant counsel | Kevin P. Martin | Attorney | Counsel for Slayback Pharma, LLCSearch in Eureka ↗ |
| Defendant counsel | Linnea P. Cipriano | Attorney | Counsel for Slayback Pharma, LLCSearch in Eureka ↗ |
| Defendant counsel | Robert Frederickson III | Attorney | Counsel for Slayback Pharma, LLCSearch in Eureka ↗ |
| Defendant counsel | William Evans | Attorney | Counsel for Slayback Pharma, LLCSearch in Eureka ↗ |
| Defendant law firm | Goodwin Procter LLP | Law Firm | Representing Slayback Pharma, LLCSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s disposition — ‘REVERSED IN PART, VACATED, AND REMANDED’ — reflects a multi-layered appellate review under de novo and clear error standards depending on the underlying question. Reversal in part indicates the court identified at least one legal or factual error warranting correction without further fact-finding. Vacatur goes further, nullifying the operative ruling below entirely and preventing it from being cited as binding authority. Remand returns jurisdiction to the lower tribunal for proceedings consistent with the appellate court’s guidance, meaning the ultimate validity of US8293742B2 remains open.
US8293742B2 — Preferential vasoconstriction compositions and methods of use
US8293742B2 (application US12/460941) protects compositions and methods achieving preferential vasoconstriction — a pharmaceutical mechanism enabling targeted blood vessel constriction, with particular relevance to ophthalmic and nasal applications. The patent falls within the speciality pharmaceutical and drug formulation domain, where formulation-specific IP commonly forms the core of both branded product moats and ANDA litigation strategies. Its designation as a utility patent covering both composition and method claims typically affords broad enforcement potential.
In the context of generic pharmaceutical competition, composition-plus-method patents like US8293742B2 are strategically significant because they can block multiple routes to generic entry simultaneously. Slayback Pharma’s challenge — characterised as an invalidity and cancellation action — is consistent with the standard ANDA paragraph IV litigation pattern, where generics seek to clear IP before market entry. The Federal Circuit’s decision to reverse in part and remand suggests the patent’s validity is not yet settled, making it a live risk for any competitor active in the vasoconstriction formulation space.
Should you run an FTO against US8293742B2?
Any company developing, manufacturing, or commercialising preferential vasoconstriction compositions — including ophthalmic decongestants, nasal vasoconstrictors, or related formulations — should treat US8293742B2 as requiring active FTO analysis. The Federal Circuit’s vacatur of the lower invalidity determination means prior clearance opinions referencing that ruling are no longer reliable. R&D teams working on vasoconstriction drug delivery should audit their formulation claims against this patent’s claim scope before advancing to IND or NDA filing.
PatSnap Eureka’s FTO Search Agent enables rapid claim-mapping against US8293742B2, surfacing relevant prior art, identifying design-around opportunities, and flagging related continuation or divisional applications in the same family. Given that the remand may produce amended claim constructions, real-time patent monitoring via Eureka ensures your FTO position remains current as the litigation evolves — without requiring manual docket review.
Run a freedom-to-operate analysis on US8293742B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit pharmaceutical patentability appeals
Federal Circuit appeals involving pharmaceutical composition patent invalidity challenges — particularly in the vasoconstriction and ophthalmic drug space — with comparable reversal and remand outcomes.
What this case signals for the pharmaceutical patent IP landscape
A Federal Circuit reversal and remand in a patentability dispute reshapes risk calculations for generic entrants and patent holders alike.
Vacatur resets the invalidity record — prior decisions cannot be relied upon
Companies that were tracking the lower tribunal’s invalidity analysis as a basis for FTO clearance must now treat that analysis as nullified. The Federal Circuit’s vacatur strips the prior decision of precedential and practical effect. Any FTO or freedom-to-commercialise opinion referencing that ruling should be revisited before product launch or licensing negotiations.
Partial appeal dismissal signals procedural complexity — watch for standing issues
The court’s partial dismissal of the appeal suggests that not all issues or parties cleared appellate procedural hurdles. This is a common pattern in ANDA-adjacent or multi-claim invalidity proceedings. IP teams monitoring this dispute should assess whether the dismissed portion relates to specific patent claims, specific parties, or time-sensitive product approval timelines.
Eye v Slayback — key questions answered
The Federal Circuit issued a compound ruling: reversed in part, vacated, and remanded. This means the court found legal error in part of the lower tribunal’s patentability determination regarding US8293742B2, nullified the operative decision, and sent the matter back for further proceedings. The partial dismissal of the appeal suggests certain issues did not clear appellate procedural thresholds.
US8293742B2 (application US12/460941) covers preferential vasoconstriction compositions and methods of use — a pharmaceutical patent relevant to ophthalmic and nasal drug formulations. Slayback Pharma, a generic pharmaceutical company, challenged its validity in proceedings characterised as an invalidity and cancellation action, consistent with the ANDA litigation pattern where generics seek to clear blocking IP before market entry.
Vacatur strips the lower tribunal’s ruling of legal effect, meaning any invalidity finding that stood below can no longer be relied upon. Reversal in part indicates the Federal Circuit corrected at least one specific error. Remand means a lower tribunal must re-examine the validity questions with the benefit of the Federal Circuit’s guidance. US8293742B2’s validity remains unresolved pending those remand proceedings.
A partial dismissal suggests that some issues presented on appeal were not properly before the Federal Circuit — potentially due to lack of standing, mootness, or procedural deficiency. The public record does not specify which issues were dismissed. This limits the scope of the appellate ruling and may leave certain invalidity arguments available to Slayback for re-litigation at the remand stage.
Yes. The Federal Circuit’s vacatur of the lower invalidity determination removes any FTO clearance that depended on that ruling. Companies developing or launching vasoconstriction compositions should commission an updated FTO analysis against US8293742B2 before progressing commercial or regulatory milestones. Monitoring the remand proceedings is also advised, as amended claim constructions could broaden or narrow the patent’s effective scope.
PatSnap Eureka searches patents and litigation data to answer instantly.